Matches in Wikidata for { <http://www.wikidata.org/entity/Q96684866> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q96684866 description "article scientifique publié en 2020" @default.
- Q96684866 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96684866 description "scientific article published on 25 June 2020" @default.
- Q96684866 description "wetenschappelijk artikel" @default.
- Q96684866 description "наукова стаття, опублікована 25 червня 2020" @default.
- Q96684866 description "գիտական հոդված հրատարակված 2020 թվականի հունիսի 25-ին" @default.
- Q96684866 name "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 name "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 type Item @default.
- Q96684866 label "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 label "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 prefLabel "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 prefLabel "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 P1433 Q96684866-FC3A5403-8863-414C-9735-A92F074EE13F @default.
- Q96684866 P1476 Q96684866-B69CAA4A-EF77-4D15-A822-5343ABF99777 @default.
- Q96684866 P2093 Q96684866-0FAA1AF0-6306-4BA2-8CF6-1AA6B256EDB2 @default.
- Q96684866 P2093 Q96684866-3441B5CF-4116-40DD-B646-4698701D40B9 @default.
- Q96684866 P2093 Q96684866-5F2D7E9A-12E6-4F26-A296-22FF6AC93884 @default.
- Q96684866 P2093 Q96684866-8F2E5634-A5A8-47A0-BD63-D6E7A0BD8F78 @default.
- Q96684866 P2093 Q96684866-C98177E1-A010-44AB-991B-514801DEB0C8 @default.
- Q96684866 P2093 Q96684866-F62E0CF0-836F-45F6-95A6-9D4E4FD8E7C8 @default.
- Q96684866 P2860 Q96684866-94656DE0-84F4-4FBA-8B33-C58EB59D9059 @default.
- Q96684866 P31 Q96684866-BD06E5D9-92BF-4385-A572-9AA9243F2F9C @default.
- Q96684866 P356 Q96684866-906EA1CA-68CB-4996-A614-590DB43ED158 @default.
- Q96684866 P50 Q96684866-14C91C95-63C1-4575-BE53-21E32BAAF26C @default.
- Q96684866 P50 Q96684866-9EA91D72-EBDB-4334-9FF0-7C2769D7AE4C @default.
- Q96684866 P50 Q96684866-CDFC89CC-7DD6-4D7F-AD31-6F11D1119C74 @default.
- Q96684866 P577 Q96684866-39BC48B2-C707-4276-9C65-0DBC8506094D @default.
- Q96684866 P698 Q96684866-DA85A846-26D4-4C99-958A-9AD65A40A114 @default.
- Q96684866 P921 Q96684866-B673E31A-199D-444B-8FBA-87B903C4F033 @default.
- Q96684866 P356 0008-5472.CAN-19-3822 @default.
- Q96684866 P698 32586982 @default.
- Q96684866 P1433 Q326097 @default.
- Q96684866 P1476 "NRAS status determines sensitivity to SHP2 inhibitor combination therapies targeting the RAS-MAPK pathway in neuroblastoma" @default.
- Q96684866 P2093 "Claire M Robinson" @default.
- Q96684866 P2093 "Ivette Valencia-Sama" @default.
- Q96684866 P2093 "Lynn Kee" @default.
- Q96684866 P2093 "Meredith S Irwin" @default.
- Q96684866 P2093 "Michael Ohh" @default.
- Q96684866 P2093 "Teresa Adderley" @default.
- Q96684866 P2860 Q24655923 @default.
- Q96684866 P31 Q13442814 @default.
- Q96684866 P356 "10.1158/0008-5472.CAN-19-3822" @default.
- Q96684866 P50 Q60311553 @default.
- Q96684866 P50 Q96684863 @default.
- Q96684866 P50 Q96684864 @default.
- Q96684866 P577 "2020-06-25T00:00:00Z" @default.
- Q96684866 P698 "32586982" @default.
- Q96684866 P921 Q938205 @default.